CDT Equity Inc. (CDT) Stock Score, Valuation & Financial Research

CDT Equity Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CDT

CDT Equity Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.93. These figures are a research snapshot, not a buy or sell recommendation.

What CDT Equity Inc. does

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

CDT Equity Inc. operates as a data-driven biopharmaceutical company that focuses on identifying, enhancing, and advancing clinical-stage therapeutic assets. The company utilizes a lean, asset-agnostic business model, conducting preclinical studies and early-stage clinical development with the primary objective of licensing these assets to third parties for further development and commercialization.

Products and services

  • The company's clinical pipeline includes AZD1656 (glucokinase activator for autoimmune disorders), AZD5658 (for Type 2 Diabetes Mellitus), and AZD5904 (for idiopathic male infertility).

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CDT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.93
Market capitalization:
716.85K (currency not supplied)
Revenue:
USD 1.45B
Net income:
USD 91.12M
Free cash flow:
USD -17.96M
Cash:
USD 348.66M
Total debt:
USD 1.32B
EPS:
USD -5669.00

What stands out

  • Free cash flow is USD -17.96M, negative for the stored period.
  • The balance sheet shows USD 348.66M of cash versus USD 1.32B of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -1.2% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals 6.3% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 970.57M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CDT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CDT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is CDT's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CDT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research CDT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.